Market Closed -
Nyse
21:00:02 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
106.5
USD
|
+1.41%
|
|
+6.39%
|
+33.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,011
|
3,382
|
2,083
|
2,082
|
3,877
|
5,343
|
-
|
-
|
Enterprise Value (EV)
1 |
1,837
|
3,227
|
2,021
|
2,082
|
3,935
|
5,451
|
5,478
|
5,343
|
P/E ratio
|
147
x
|
-27.9
x
|
-41.5
x
|
-20.9
x
|
-28.6
x
|
-41.9
x
|
-61
x
|
-96.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.49
x
|
15
x
|
7.08
x
|
7.36
x
|
12.3
x
|
14.8
x
|
12.1
x
|
9.84
x
|
EV / Revenue
|
7.75
x
|
14.3
x
|
6.87
x
|
7.36
x
|
12.5
x
|
15.1
x
|
12.4
x
|
9.84
x
|
EV / EBITDA
|
-41.8
x
|
-34.3
x
|
258
x
|
-37.8
x
|
-56.1
x
|
-67.3
x
|
-106
x
|
431
x
|
EV / FCF
|
-361
x
|
-108
x
|
-87.6
x
|
-32.9
x
|
-50.4
x
|
-114
x
|
-76.4
x
|
88.3
x
|
FCF Yield
|
-0.28%
|
-0.93%
|
-1.14%
|
-3.04%
|
-1.98%
|
-0.88%
|
-1.31%
|
1.13%
|
Price to Book
|
3.52
x
|
5.1
x
|
3.55
x
|
3.94
x
|
8.46
x
|
11.1
x
|
10.4
x
|
8.88
x
|
Nbr of stocks (in thousands)
|
36,917
|
44,933
|
46,862
|
47,675
|
48,772
|
50,160
|
-
|
-
|
Reference price
2 |
54.47
|
75.26
|
44.44
|
43.68
|
79.49
|
106.5
|
106.5
|
106.5
|
Announcement Date
|
27/02/20
|
25/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
237
|
225
|
294
|
282.9
|
314.7
|
361.8
|
443.4
|
542.7
|
EBITDA
1 |
-43.99
|
-94.17
|
7.825
|
-55.13
|
-70.13
|
-81.03
|
-51.45
|
12.41
|
EBIT
1 |
-50.29
|
-48.21
|
-21.84
|
-86.7
|
-103.8
|
-105.2
|
-69.15
|
-31.54
|
Operating Margin
|
-21.22%
|
-21.43%
|
-7.43%
|
-30.65%
|
-32.98%
|
-29.08%
|
-15.6%
|
-5.81%
|
Earnings before Tax (EBT)
1 |
-50.04
|
-132.3
|
-
|
-
|
-133.7
|
-115
|
-94.68
|
-75.3
|
Net income
1 |
15.42
|
-120.3
|
-49.59
|
-99.2
|
-134.7
|
-127.9
|
-79.8
|
-57.67
|
Net margin
|
6.51%
|
-53.5%
|
-16.87%
|
-35.07%
|
-42.79%
|
-35.35%
|
-18%
|
-10.63%
|
EPS
2 |
0.3700
|
-2.700
|
-1.070
|
-2.090
|
-2.780
|
-2.541
|
-1.747
|
-1.104
|
Free Cash Flow
1 |
-5.093
|
-29.92
|
-23.08
|
-63.35
|
-78.01
|
-47.95
|
-71.7
|
60.5
|
FCF margin
|
-2.15%
|
-13.3%
|
-7.85%
|
-22.4%
|
-24.79%
|
-13.25%
|
-16.17%
|
11.15%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
487.53%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
74.71
|
73.24
|
67.68
|
72.68
|
71.27
|
71.23
|
73.9
|
80.4
|
78.05
|
82.36
|
85.62
|
88.61
|
89.74
|
98.98
|
103
|
EBITDA
1 |
18.41
|
-2.813
|
-6.028
|
-21.1
|
-7.394
|
-19.24
|
-18.46
|
-12.98
|
-13.33
|
-23.88
|
-21.68
|
-18.65
|
-19.7
|
-19.28
|
-17.44
|
EBIT
1 |
-4.859
|
-10.32
|
-13.64
|
-30.36
|
-15.29
|
-27.42
|
-26.76
|
-22.85
|
-21.78
|
-32.39
|
-32.84
|
-24.52
|
-24.06
|
-23.97
|
-20.55
|
Operating Margin
|
-6.5%
|
-14.08%
|
-20.15%
|
-41.77%
|
-21.45%
|
-38.5%
|
-36.22%
|
-28.42%
|
-27.91%
|
-39.33%
|
-38.35%
|
-27.67%
|
-26.81%
|
-24.21%
|
-19.94%
|
Earnings before Tax (EBT)
1 |
6.432
|
-22.24
|
5.703
|
-45.64
|
-27.33
|
-31.16
|
-34.22
|
-32.38
|
-30.41
|
-36.72
|
-40.46
|
-27.57
|
-26.39
|
-27.15
|
-23.38
|
Net income
1 |
6.23
|
-21.87
|
5.377
|
-45.54
|
-27.58
|
-31.46
|
-34.63
|
-32.81
|
-30.44
|
-36.78
|
-40.84
|
-29.44
|
-28.84
|
-28.96
|
-24.34
|
Net margin
|
8.34%
|
-29.86%
|
7.94%
|
-62.65%
|
-38.69%
|
-44.17%
|
-46.86%
|
-40.81%
|
-39.01%
|
-44.65%
|
-47.7%
|
-33.22%
|
-32.13%
|
-29.26%
|
-23.63%
|
EPS
2 |
0.1300
|
-0.4700
|
0.1100
|
-0.9600
|
-0.5800
|
-0.6600
|
-0.7200
|
-0.6800
|
-0.6300
|
-0.7500
|
-0.8200
|
-0.5912
|
-0.5862
|
-0.5838
|
-0.4940
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
22/02/22
|
04/05/22
|
03/08/22
|
02/11/22
|
22/02/23
|
03/05/23
|
02/08/23
|
01/11/23
|
21/02/24
|
01/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
57.9
|
109
|
135
|
-
|
Net Cash position
1 |
174
|
154
|
61.3
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.8253
x
|
-1.34
x
|
-2.631
x
|
-
|
Free Cash Flow
1 |
-5.09
|
-29.9
|
-23.1
|
-63.3
|
-78
|
-48
|
-71.7
|
60.5
|
ROE (net income / shareholders' equity)
|
3.64%
|
-7.62%
|
-6.15%
|
-18.5%
|
-22.1%
|
-23.6%
|
-16.6%
|
-4.36%
|
ROA (Net income/ Total Assets)
|
3.01%
|
-5.6%
|
-3.75%
|
-10.1%
|
-11.3%
|
-11.2%
|
-0.23%
|
4.63%
|
Assets
1 |
512.7
|
2,149
|
1,322
|
982.5
|
1,192
|
1,143
|
34,249
|
-1,245
|
Book Value Per Share
2 |
15.50
|
14.80
|
12.50
|
11.10
|
9.400
|
9.610
|
10.30
|
12.00
|
Cash Flow per Share
|
-0.0100
|
-0.5200
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.72
|
6.94
|
47.8
|
30.3
|
20.2
|
23
|
23.7
|
26.7
|
Capex / Sales
|
1.99%
|
3.08%
|
16.25%
|
10.7%
|
6.43%
|
6.36%
|
5.35%
|
4.91%
|
Announcement Date
|
27/02/20
|
25/02/21
|
22/02/22
|
22/02/23
|
21/02/24
|
-
|
-
|
-
|
Last Close Price
106.5
USD Average target price
109.1
USD Spread / Average Target +2.42% Consensus |
1st Jan change
|
Capi.
|
---|
| +33.99% | 5.27B | | -7.58% | 10.74B | | +2.17% | 8.93B | | +22.75% | 7.61B | | +8.12% | 3.42B | | -8.48% | 2.86B | | -5.07% | 2.23B | | -4.22% | 2.13B | | -20.87% | 1.84B | | -4.52% | 1.2B |
Medical Devices & Implants
|